Physiomics Share Discussion Threads

[the stigologist] 06/2/2018 16:36

Good finish on a market crash day

Great relative strength

[billthebank] 06/2/2018 16:33

Just press the Intraday chart button

[volsung] 06/2/2018 16:00

What's happened the ADVFN charts? Are they too scary to show!

[cool hand kev] 06/2/2018 15:07

Hopefully we have share price support here BWTFDIK

[margic] 06/2/2018 13:50

Next should be a collaboration deal. Ref: early October company update. Wonder how they are getting on with the prototype DSs also?

[buddugoliaeth] 06/2/2018 01:39

I don't blame you in the slightest for feeling raw after JC's utterly disgraceful intervention in PYC. He represents the very worst kind of short-termism and in my view only got away with such blatant market manipulation thanks to the deepness of his pockets. Good luck to him wherever he's gone next, but like you no doubt I'm truly thankful that he's now quit the scene here at PYC, hopefully for good.

Thanks also for your tip re WTI, which took 2nd place on the leader board yesterday behind BOX, although I have to say BOX sat comfortably at the top of the list all day at up to 53% before retracing to a 40% gain, even without any help such as WTI had from an rns.

But I'll pipe down about all this now lest it risk becoming a bore. I used to get terrible flak on the SAR bb when I tried pointing out the merits of PYC. They absolutely hated any mention of PYC back then, although now I guess they must be feeling a little sick at the well deserved transformation in PYC's profile.

On bb's like this I believe we should welcome discussion of other shares occasionally, partly in order to provide a sense of context for our investment decisions re PYC and similar shares. I'm not interested in ramping / deramping any particular share, just in sharing my honest views and feelings as a private investor swimming about like everyone else in the unpredictable seas of the market.

[billthebank] 05/2/2018 23:03

OK Fair enough Just a little raw after JCs chenanigans I wasnt in the mood to listen to ramping of another share. Perhaps if you had posted your research it might have attracted my attention. To be honest there are so many people diverting ones attention to another stock few of them actually are made without them having an agenda. Will have a look at box but looks as if I missed the boat, Good luck. Might I recommend you research Weatherly WTI. If you are bullish re Copper it is worth researching. The graph may look a little spiky but I feel there is a lot more to come.

[buddugoliaeth] 05/2/2018 20:56

Bill

To you this may seem the "wrong thread" for BOX, but to me it's valid because BOX today comes across to me much like PYC and SAR when they were unloved, scorned by the markets and wallowing in the doldrums. These are the type of shares I tend to go in for and I make it my business to lend such struggling companies my support till they finally make it and come good.

Take SAR for instance, I first invested in SAR in early 2009 when they were at 0.04p and had a mcap of around £500k. The morning after I bought 6m shares, SAR sprang into life and over 60m shares were traded in one day. Sadly as a novice investor I sold far too soon at 0.11p, only to watch helplessly as the share price went on rising to over 1p. Lesson learned!

With PYC it was much the same story, building my holding in 2016 when it was seen as a hopeless bet on a deadbeat outfit without any serious prospects. But I liked what they were doing, I wanted to support a company that was using the power of maths to help work out more effective anti-cancer dosing regimes, and I was emboldened by the arrival of Dr Jim Millen (ex-GSK)as CEO and the presence of Prof Mark Middleton (Oxford's Professor of Experimental Cancer Medicine and a leading authority in the field of melanoma)on PYC's scientific advisory board. Of course I've traded in and out of PYC in the meantime, but I'm still here with a holding so please don't knock me as a seller. The next big announcement I'm looking forward to from PYC is on the cancer treatment decision-making tool they're developing for use in the NHS, a project being taken forward under Prof Middleton's expert guidance. An update on this should be due in the coming weeks.

Of course BOX operates in a totally different field from PYC or SAR, but as I say it's a similarly unloved outfit seen as an absolute dog practically on its last legs just as they once were. For better or worse I've chosen to cherish BOX's fortunes and recognise the management and operational changes for the better they've now put in place. Will these pay off? Who can tell, but as an investor one can only live in hope.

[cool hand kev] 05/2/2018 15:38

Please can you clarify?

[margic] 05/2/2018 15:11

Golden X coming in on 240.

[billthebank] 05/2/2018 13:38

This is Physiomics not BOX!!!!!!Wrong thread

[buddugoliaeth] 05/2/2018 13:11

volly

DYOR

[volsung] 05/2/2018 12:50

Is BOX up?

[buddugoliaeth] 05/2/2018 12:49

BOX up 53%, balancing my PYC holding nicely.

[buddugoliaeth] 05/2/2018 12:07

BOX up 33%, great day so far.

[buddugoliaeth] 05/2/2018 11:29

Glad to hold BOX as well as PYC. BOX is currently the stock exchange's number one riser in percentage terms. Positive trading update expected soon.

[buddugoliaeth] 05/2/2018 11:06

BOX now up 20%, interesting.

[buddugoliaeth] 05/2/2018 10:26

BOX flying this morning, all blue somewhere!

[pwhite73] 05/2/2018 09:05

Safest bet. MM will just trash short it all the way down to the next placing price.

[the stigologist] 05/2/2018 08:49

Ex Founder of Physiomics (PYC) Peter Hoskins who writes on ADVFN as "ant15"

ant15 - 30 Nov 2017 - 15:07:26 - 3710 of 4892

Writing as a Founder of Physiomics

I am a shareholder but do not represent the company in any capacity.

WHY THIS SHARE IS WORTH A £1.00 giving it a market cap of still less than £60.million

*It is first to market

*Scarcity of trained personnel in what is still an emergent technology ( there are currently over a 1000 vacancies to be filled in this sector and few trained personnel )

*The development time needed to populate models and most importantly the availability of patient data that needs to be accessed apart from what is available in the literature is protracted PYC has been through this curve perfecting its models over time.

* The Biometric Grant serves to demonstrate not only the faith in the company but also underpins the access PYC is being given to Patient data In this case in the field of Oesophgeal Cancer

*Collaborations with major pharmas have been constrained whilst the models are perfected and due to the secretive nature of all pharmas who generally speaking do not want to share data. The latest contract has dramatically increased the visibility of what PYC do and do best and will encourage a raft of Biotech analysts to write it up as more contracts are announced

*PYC's Cardiac Toxicity Model is 50% plus better than any other available on the market Why is this important? it is the major cause of attrition in clinical trials
( drug failure )

*The cost savings PYC is able to realise for major Pharma is key and further to small Biotechnology companies whose funding is limited as they try to move molecules into clinical trials.

* Big Pharmas feed their development pipelines by acquiring or licensing in small bio's however these sales have moved progressively from Targets 20 years ago to IND candidates and onto Phase 1/2 putting the burden of proof onto the small Bio Techs who need to conserve and raise cash ( not easy and never has been )

*In 2010 Scientific American stated the cost of Development of a drug from start to finish FDA approval was $1.4 billion...In 2016 Association of British Pharmaceutical Industry Has upped this to £1.5 billion ( sterling) a really significant increase. NOTING that only 1 in 5000 drugs get final approval and this is not factored into the costs as above as representing only a successful transition of 1 drug to approval

*In America alone $12-%14 billion per year is spent on Animal Testing Robert Solari a senior research fellow at Imperial College states "The predictive power of biology in reseach is relatively poor in research labs" and notes that the efficacy of animal testing are not particulary predictive of Human Efficacy PYC is "in Silico" ( in computer) its accuracy is one of its major plus points

* PYC is striving to personalised medicine The HOLY GRAIL with tremendous Social and Financial Implications.

* Sooner rather than later The FDA in America will have to recognise that rational drugs designed in computers can be tested in them too saving countless millions of development costs and most importantly time taken to approval ie move from the 20 to the 21st century

* PYC has taken time to develop its excellent technology I believe I have cited the reasons for its true value. It has been challenged in recent times but has now become of age an is exceptionally well positioned in a market sector that is set to expand exponentially.

To recap A leading British Technology currently way undervalued and one that is not a speculative BUY It has proven technology in a burgeoning sector and might well become the focus of an acquisition target as it is still so undervalued

[pwhite73] 05/2/2018 08:31

The stock has risen 700% since 28/11/2017. Sit here and watch it crash back down to 2p.